Strategic asset sale Opportunity to engage MediciNova-like buyers or royalty/asset purchasers who may value Avigen's AAV assets and related IP as underpriced upside potential.

Leadership transition Recent CEO retirement signals potential openness to strategic partnerships or advisory roles; approach with careful timing around leadership changes and governance updates.

Funding profile Revenue range suggests a midsize biotech with burn and financing needs; explore collaborations, licensing deals, or co-development arrangements to align with budget cycles.

Technical footprint GoDaddy as tech stack hint; potential for digital marketing, online sponsorships, or platform partnerships to improve visibility, investor relations, and talent outreach.

Biotech alignment Similar company peers operate at scale; position Avigen for strategic partnerships with larger biotechs for asset monetization, research collaborations, or manufacturing/clinical development support.